Japanese Dainippon's Phase III Schizophrenia Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa

Dainippon Sumitoma Pharma Co. does have enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but the newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at U.S. FDA